Login
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC.

ptcbio.com

What Do They Do?

Develops and sells medicines for rare disorders, including treatments for metabolic and neurological diseases, for children and adults.

How Do They Make Money?

Partners pay upfront license fees, milestone payments and royalties on future product sales; the company also earns fees for research and development services. Medicine customers are generally invoiced after delivery, though some countries pay in advance.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Net product revenue
Sold outright

34%
FY2022: 77%
Collaboration and license revenue
Licensed

58%
Royalty revenue
Licensed

14%
FY2022: 16%
Manufacturing revenue
0.0%
FY2022: 0.0%

Who Are Their Customers?

Medicine orders come from distributors, hospitals, specialty pharmacies and retail pharmacies; pharmaceutical collaborators license programs and may fund research and development.

Do Revenues Turn Into Profits?

Yes. It kept 39 cents of every revenue dollar as net income in FY2025 and turned 41 cents into free cash flow.

Operating income, FY2025
50% of revenue
▲ Turned profitable vs FY2024 (−$302.6M, −38%)
Net income, FY2025
39% of revenue
▲ Turned profitable vs FY2024 (−$363.3M, −45%)
Free cash flow, FY2025
41% of revenue
▲ Turned profitable vs FY2024 (−$114.2M, −14%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +70%
vs $211M in Q3 FY2025
Net income
▼ Turned to a loss
vs $15.9M in Q3 FY2025
Collaboration and license revenue share of revenue vs 4.4% in Q3 FY2025
  • Aug 28, 2026 Agreed to acquire ST-920 gene therapy program for Fabry disease The asset purchase remains subject to bankruptcy court approval, antitrust review and other closing conditions.
  • Jul 30, 2026 Raised full-year revenue guidance and lifted product revenue forecast Full-year total revenue is expected at $1.18 to $1.28 billion, with product revenue guided to $850 to $950 million.

Growing. Revenue grew 3.2x in 4 years, from $538.6M in FY2021 to $1.7B in FY2025, about 34% a year.

Sephience's status Sephience advanced from a clinical-stage PKU candidate to an approved product for children and adults.

Translarna's EEA authorization Translarna had marketing authorization in the EEA for nmDMD; the latest report says the European Commission adopted a decision not to renew it, while individual EU countries may allow continued use.

Revenue over time
Net product revenue Collaboration and license revenue Royalty revenue Manufacturing revenue Collaboration revenue
$2B$1B$0

Who Do They Compete With?

Competes with Otsuka Pharmaceutical, SOM Biotech, Maze Therapeutics, Agios Pharmaceuticals, Santhera Pharmaceuticals, Sarepta Therapeutics, NS Pharma, Dyne Therapeutics, Wave Life Sciences, Daiichi Sankyo, Nippon Shinyaku, Solid Biosciences, REGENXBIO, Alnylam Pharmaceuticals, Pfizer, BridgeBio Pharma, Intellia Therapeutics, Biogen, Novartis, and uniQure

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support